[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345524-105":59,"doc-detail-345524-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mdm2-inhibitors-in-myeloid-cancers-from-basic-biology-to-clinical-use-in-myeloproliferative-neoplasms","MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms","","MDM2 inhibitors are presented as a therapeutically instructive strategy in hematologic oncology, focused on reactivating wild-type p53 in myeloid malignancies. The MDM2–p53 autoregulatory loop is described as a central controller of cellular stress responses, with p53 often retained yet functionally suppressed by MDM2 overexpression and oncogenic signaling, especially JAK–STAT in myeloproliferative neoplasms. The review synthesizes mechanistic biology, clinical translation, dosing and toxicity lessons, biomarker-guided selection, and resistance pathways. It also discusses emerging response data, resistance biology including TP53-mutant clonal selection, and future directions such as rational combinations and next-generation MDM2 degraders.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mdm2-inhibitors-in-myeloid-cancers-from-basic-biology-to-clinical-use-in-myeloproliferative-neoplasms/345524/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mdm2-inhibitors-in-myeloid-cancers-from-basic-biology-to-clinical-use-in-myeloproliferative-neoplasms/345524.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are MDM2 inhibitors considered a strategy to reactivate p53 in myeloid cancers?","Question",{"text":112,"@type":113},"MDM2 is the primary negative regulator of p53. In many myeloid malignancies, p53 is retained in wild-type form but is functionally suppressed through MDM2 overexpression and oncogenic signaling, enabling p53 reactivation when MDM2 is inhibited.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the role of the MDM2–p53 autoregulatory loop in cellular stress responses?",{"text":117,"@type":113},"The loop is described as a central regulator of cellular stress responses, coordinating how cells respond to stress via p53 control and its regulation by MDM2.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical and translational challenges does the review emphasize?",{"text":121,"@type":113},"The review highlights key issues including dosing paradigms, hematologic toxicity, biomarker-driven patient selection, and mechanisms of resistance, such as TP53-mutant clonal selection. It also notes that early phase III trials in AML were negative while more recent studies in myelofibrosis show clinically meaningful responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345524,1790169480,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Leukemia [www.nature.com/leu](www.nature.com/leu)  \nREVIEW ARTICLE OPEN   \nMDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms  \nHaifa K. Al-Ali 1, Sarah T. Heidel2, Francesca Palandri 3 and Florian H. Heidel 4 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies. The MDM2–p53 autoregulatory loop is a central regulator of cellular stress responses, and in myeloid neoplasms—including acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN)—p53 is frequently retained but functionally suppressed through MDM2 overexpression and oncogenic signaling, notably via JAK–STAT activation. Over the past decade, successive generations of MDM2 inhibitors have translated structural and mechanistic insights into clinical investigation, yielding critical lessons regarding dosing paradigms, hematologic toxicity, biomarker-driven patient selection, and mechanisms of resistance, including TP53-mutant clonal selection. While early phase III trials in AML were negative, recent studies in myelofibrosis demonstrate clinically meaningful spleen, symptom, and molecular responses, supporting disease-modifying potential in TP53–wild-type settings. Adaptive platform designs and rational combinations with JAK inhibitors, BCL-2 antagonists, and interferons have further refined therapeutic strategies. Emerging MDM2 degraders and next-generation agents aim to overcome feedback limitations and improve therapeutic index. This review integrates mechanistic foundations, clinical development, resistance biology, and future directions, highlighting how decades of basic science have reshaped p53 |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| reactivation into a precision therapeutic paradigm in myeloid disease. |  |  |\n|  | Leukemia (2026) 40:1111–1121; [https://doi.org/10.1038/s41375-026-02975-6](https://doi.org/10.1038/s41375-026-02975-6) |  |\n|  |  |  |\n\nOVERVIEW  \nThe pharmacologic targeting of murine double minute 2 (MDM2) has emerged as one of the most conceptually elegant and clinically instructive advances in modern hematologic oncology. Rooted in fundamental discoveries defining the MDM2–TP53 autoregulatory loop as a master regulator of cellular stress responses, this field has progressed from structural and biochemical insight into a clinically actionable strategy for reactivating endogenous tumor suppressor function. In myeloid malignancies—particularly myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML)—where TP53 is frequently retained in its wild-type form but functionally restrained, MDM2 inhibition offers a unique opportunity to therapeutically exploit an intact but suppressed p53 pathway. Over the past decade, successive generations of MDM2 inhibitors have translated these principles into the clinic, yielding critical lessons regarding target biology, dosing paradigms, toxicity management, clonal evolution, and biomarker-driven patient selection. At the same time, emerging data have revealed MDM2 as a convergence point for oncogenic signaling, inflammatory cues, and cytokine-driven pathways—most notably JAK–STAT signaling in MPN—thereby positioning MDM2 inhibition not merely as a cytotoxic strategy, but as a potential disease-modifying intervention.  \nIn this review, we integrate mechanistic foundations of the MDM2–p53 axis with the evolution of MDM2 inhibitor  \ndevelopment, summarize key clinical experiences across myeloid neoplasms, and discuss resistance mechanisms, safety considerations, and future directions, including rational combination strategies and next-generation approaches such as MDM2 degraders. Together, these insights delineate how decades of basic biology have culminated in a therapeutic paradig","cbCaicCCIQpzkRIE","https://ap.wps.com/l/cbCaicCCIQpzkRIE","pdf",1086021,11,"English","# Overview\n# Mechanistic Foundations: The MDM2-TP53 Axis in Cellular Homeostasis\n## Structural and Functional Architecture of MDM2","[{\"question\":\"Why are MDM2 inhibitors considered a strategy to reactivate p53 in myeloid cancers?\",\"answer\":\"MDM2 is the primary negative regulator of p53. In many myeloid malignancies, p53 is retained in wild-type form but is functionally suppressed through MDM2 overexpression and oncogenic signaling, enabling p53 reactivation when MDM2 is inhibited.\"},{\"question\":\"What is the role of the MDM2–p53 autoregulatory loop in cellular stress responses?\",\"answer\":\"The loop is described as a central regulator of cellular stress responses, coordinating how cells respond to stress via p53 control and its regulation by MDM2.\"},{\"question\":\"What clinical and translational challenges does the review emphasize?\",\"answer\":\"The review highlights key issues including dosing paradigms, hematologic toxicity, biomarker-driven patient selection, and mechanisms of resistance, such as TP53-mutant clonal selection. It also notes that early phase III trials in AML were negative while more recent studies in myelofibrosis show clinically meaningful responses.\"}]","MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms | PDF",1790057967,28]